Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received European Commission, or EC, approval of a new Opdivo – nivolumab – subcutaneous formulation developed with Enhanze, Halozyme’s proprietary recombinant human hyaluronidase enzyme, for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. The positive EC decision is supported by positive results from the Phase 3 CheckMate -67T trial. The approval by the EC is valid in all 27 member states of the European Union, as well as Iceland, Liechtenstein and Norway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Optimistic Buy Rating for Halozyme Amid Price Control Concerns
- Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
- Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme
- UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
- Halozyme, J&J slide as analyst cuts rating on CMS draft guidance